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The persistence of Mycobacterium tuberculosis is a major cause of concern in tuberculosis (TB) therapy. In
the persistent mode the pathogen can resist drug therapy, allowing the possibility of reactivation of the disease.
Several protein factors have been identified that contribute to persistence, one of them being the 16-kDa
low-molecular-weight mycobacterial heat shock protein Hsp16.3, a homologue of the mammalian eye lens
protein alpha-crystallin. It is believed that Hsp16.3 plays a key role in the persistence phase by protecting
essential proteins from being irreversibly denatured. Because of the close association of Hsp16.3 with persis-
tence, an attempt has been made to develop inhibitors against it. Random peptide libraries displayed on
bacteriophage M13 were screened for Hsp16.3 binding. Two phage clones were identified that bind to the
Hsp16.3 protein. The corresponding synthetic peptides, an 11-mer and a 16-mer, were able to bind Hsp16.3 and
inhibit its chaperone activity in vitro in a dose-dependent manner. Little or no effect of these peptides was
observed on alphaB-crystallin, a homologous protein that is a key component of human eye lens, indicating
that there is an element of specificity in the observed inhibition. Two histidine residues appear to be common
to the selected peptides. Nuclear magnetic resonance studies performed with the 11-mer peptide indicate that
in this case these two histidines may be the crucial binding determinants. The peptide inhibitors of Hsp16.3
thus obtained could serve as the basis for developing potent drugs against persistent TB.
Drug resistance is a major problem in the therapy of tuber-
culosis (TB). Such resistance arises not only due to mutations
but also due to the ability of the TB pathogen Mycobacterium
tuberculosis to enter into a dormant phase in which it can
persist for prolonged periods of time (9). This happens partic-
ularly when it is encapsulated within a granuloma—a structure
formed by the activated monocyte-macrophage system of the
host. The conditions within the granuloma are far from ideal
for mycobacterial growth (24). In particular, M. tuberculosis is
an aerobic organism, whereas the conditions within the gran-
uloma are anaerobic. Although under such conditions active
growth is halted, the bacteria can persist indefinitely by enter-
ing into a dormant phase. Drug therapy further accelerates the
shift from the active to the dormant or persistent phase (9, 24).
Treatment with the presently available drugs therefore can
potentially cause the accumulation of dormant bacilli (17),
which can reactivate themselves at a later stage.
Hsp16.3 was initially identified as a 14-kDa immunodomi-
nant antigen (26) but subsequently characterized to be a mo-
lecular chaperone that functions by preventing the aggregation
of proteins under stress conditions (7). Hsp16.3 belongs to the
alpha-heat shock protein (HSP) family of proteins represented
by the small molecular weight heat shock proteins alpha-crys-
tallin A and B, which play an important role in the mainte-
nance of the transparency of vertebrate eye lenses (25). The
expression of the mycobacterial alpha-HSP (Hsp16.3) has
been found to be induced during the course of in vitro infec-
tion of macrophages (30). When the gene for Hsp16.3 (acr) of
M. tuberculosis was deleted, the resulting strain was shown to
be equivalent to the wild-type H37Rv in in vitro growth rate
and infectivity but was significantly impaired for growth in both
mouse bone marrow-derived macrophages and THP-1 cells
(31). Deletion of the acr gene also resulted in the virulent
strain of M. tuberculosis becoming attenuated. It has been
claimed that such attenuated strains, in which Hsp16.3 expres-
sion is impaired, could be used as anti-TB vaccines (3a).
Based on the available evidence, it is generally considered
that Hsp16.3 is a potentially important component, which fa-
cilitates the survival of M. tuberculosis during latent human
infection (31). Hence, Hsp16.3 may be regarded as a possible
target for anti-TB drug discovery. However, due to the lack of
a crystal or nuclear magnetic resonance (NMR) structure, a
structure-based drug design is not possible at present. One of
the ways to develop specific inhibitors is to look for binding
peptides against a target protein by using the phage display
technique (22) and then develop peptidomimetics (2) to inhibit
its activity. We report here the identification of peptides by
phage display that bind to Hsp16.3 protein and inhibit its
chaperone activity. The putative binding determinants have
also been identified. Although as of now there is little evidence
to suggest that the approach would lead to novel therapeutics,
it would be interesting to look for anti-Hsp16.3 compounds
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through peptidomimetics for exploring new methods to com-
bat latent TB.
MATERIALS AND METHODS
Bacterial strains and plasmids. The protein Hsp16.3 was obtained from the
Escherichia coli strain EC-16, which harbors a recombinant plasmid comprising
the acr gene (Rv2031c) cloned in the E. coli expression vector pQE-8
(QIAGEN, Inc., Stanford, CA). The strain EC-16 was obtained on the basis of
a material transfer agreement with the Medical Research Council of London.
The protein is expressed from the recombinant plasmid as a fusion protein with
a stretch of His6 residues at the N-terminal end. The recombinant alphaB-
crystallin (5) expressed from a similar recombinant construct was obtained as a
gift from K. P. Das of Bose Institute, Calcutta, India.
Expression and purification of Hsp16.3. EC-16 cells were grown at 37°C under
shaking conditions in 2 YT medium containing 100 g of ampicillin/ml and
50 g of kanamycin/ml and then induced (at an A600 of 0.6) with 1 mM IPTG
(isopropyl--D-thiogalactopyranoside; Sigma, St. Louis, MO) for 4 h. Cells were
harvested by centrifugation, washed with phosphate-buffered saline, and frozen
at 20°C until use. After resuspension in buffer A (50 mM sodium phosphate [pH
7.5], 300 mM NaCl, 10 mM imidazole) containing 1 mM phenylmethylsulfonyl
fluoride (Sigma, St. Louis, MO), a protease inhibitor, cells were disrupted by using
a Labsonic-L sonicator (B. Braun, Germany), while cooling on ice, by giving 10
pulses (30 s each at 150 W) at intervals of 2 to 3 min. After centrifugation at 14,000
g, the clear supernatant was loaded onto a 4-ml Ni2-nitrilotriacetic acid (NTA)
agarose column (QIAGEN), preequilibrated with buffer A. The column was washed
with about 5 column volumes of buffer B (50 mM sodium phosphate [pH 7.5], 300
mM NaCl, 20 mM imidazole), and the bound protein was eluted with a 50 to 400
mM imidazole gradient in 50 mM sodium phosphate (pH 7.5) buffer containing 300
mM NaCl. Fractions were collected and analyzed by 15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The fractions containing pure
Hsp16.3 protein were pooled and dialyzed against 50 mM sodium phosphate (pH
7.5) buffer containing 300 mM NaCl. The Hsp16.3 protein obtained by this method
was 98% pure, as judged by SDS-PAGE. The concentration of Hsp16.3 protein
was determined on the basis of its molar extinction coefficient (3,840 M1 cm1) and
the Lowry method (16).
Screening of phage display libraries. Phage display libraries (New England
Biolabs, Inc., Beverly, MA) contained rationally designed combinatorial libraries
of peptide sequences (7-mer or 12-mer) inserted into the NH2 terminus of the
pIII minor coat protein of the M13 bacteriophage. These libraries (termed Ph.D.-7
and Ph.D.-12) contained either 7 amino acids (for the Ph.D.-7 library) or 12 amino
acids (for the Ph.D.-12 library). The peptides were followed by a short spacer
(Gly-Gly-Gly-Ser) and then the wild-type pIII sequence. The library consists of
2.8  109 electroporated sequences (compared to 207  1.28  109 possible 7- or
12-residue sequences). The libraries were screened by biopanning using standard
methods with a few modifications. Briefly, a 996-well microtiter plate was coated
with 30 g of Hsp16.3/well in 0.1 M NaHCO3 buffer (pH 8.6) and incubated
overnight at 4°C with gentle agitation in a humidified chamber. The coating solution
was poured off, and each well was completely filled with blocking buffer (5 mg of
bovine serum albumin [BSA]/ml in 0.1 M NaHCO3 buffer [pH 8.6]) and incubated
for 1 to 2 h at 4°C. Protein-coated wells were washed with TBST (Tris-buffered saline
[TBS] plus 0.1% [vol/vol] Tween 20) at least five to six times before use for biopan-
ning of phage libraries. A Ph.D.-7/Ph.D.-12 phage library containing 1011 PFU was
incubated in the wells for 1 h at room temperature on a rocker. Nonbinding phage
was poured off, and the wells were washed 10 times with TBST. Phage bound to the
Hsp16.3 protein was eluted with 0.2 M glycine-HCl buffer (pH 2.2) containing 1 mg
of BSA/ml. After elution the acidic buffer was neutralized with 1 M Tris-HCl
(pH 9.1). The eluted phage was then amplified in vivo on an E. coli ER2738 host
strain obtained from New England Biolabs, Inc. (Beverly, MA), purified by double
precipitation in cold with 1/6 volume of polyethylene glycol (PEG)-NaCl (20%
[vol/vol] PEG 8000, 2.5 M NaCl) and used in second round of biopanning. In first,
second, and third rounds of biopanning, the Tween 20 concentration was increased
progressively from 0.1 to 0.3 to 0.5%, respectively, for better washing off of non-
specifically adhered phage. After three rounds of positive selection, E. coli ER2738
cells were infected with the eluted phage and grown on LB-agar plates coated
with X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside)/IPTG. Individual
plaques were picked and amplified, and single-stranded phage DNA was isolated for
sequencing.
Reverse phage ELISA. A reverse phage enzyme-linked immunosorbent assay
(ELISA) was used to evaluate the ability of individual phage clones to bind to
Hsp16.3. Briefly, 30 g of Hsp16.3/well in 0.1 M NaHCO3 buffer (pH 8.6) was
added to a 96-well microtiter plate and blocked with 2% skim milk powder in
TBS. BSA (30 g/well) was used as a negative control. The selected peptide
phage clones, amplified and concentrated by the PEG-NaCl precipitation
method, were added to each coated well (107 to 108 PFU/well) and incubated for
2 h at room temperature. Unbound phage was removed by washing with TBST
(0.5% Tween 20), and bound phage was detected with horseradish peroxidase-
conjugated anti-M13 monoclonal antibody (Amersham Pharmacia Biotech,
Uppsala, Sweden) at 1:5,000 and with ABTS [2,2	azinobis(3-ethylbenzthiazoline-
sulfonic acid)] substrate (Roche, Mannheim, Germany). Plates were read at an
A405. If the phage clones obtained after screening are true Hsp16.3 binders, then
ELISA signals substantially higher than the background are obtained.
Synthesis and labeling of peptides. Peptides were produced on a 0.12-mmol
scale using a Biolynx 4175 peptide synthesizer. They were synthesized by the
solid-phase method with the standard Fmoc (9-fluorenylmethoxy carbonyl)
chemistry. The peptides were synthesized with their C terminus amidated by
using MBHA-Rink amide resin (Novabiochem, San Diego, CA). Amino acids
(Novabiochem) except those stated below were used as N-terminally Fmoc
protected and C-terminally pentafluorophenyl ester activated with N-hydroxy-
benzotriazole (Novabiochem, San Diego, CA). Thr, His, Arg, Ile, Ser, Ala and
Pro were used in the COOH form using benzotriazole-1-yloxytripyrrolidinophos-
phoriumhexafluorophosphate (PyBop; Novabiochem, San Diego, CA) as the
activating agent with N-hydroxybenzotriazole and N,N-diisopropylethylamine
(DIPEA; Fluka Chemie, GmbH) (1:1:2). The Fmoc-protecting group was re-
moved from the N terminus of the peptide resin by 20% piperidine in dimethyl
formamide (DMF; Merck, Germany), followed by washes with DMF. The resin
was dried under vacuum. The peptides were cleaved by using standard trifluoro-
acetic acid (TFA; Spectrochem, Mumbai, India) cleavage procedures, followed
by multiple ether extractions. Both the peptides were purified by reversed-phase
high-pressure liquid chromatography on a C18 column (Vydac, Hesperin, CA)
using a 0 to 60% acetonitrile gradient in 0.1% TFA and characterized by NMR.
A part of the resin-bound peptides was labeled with fluorescein isothiocyanate
(FITC), thus placing the fluorophore on the N terminus of the peptide. One
equivalent of dried resin in 2% piperidine in DMF was mixed with 30 eq of FITC
(Molecular Probes, Inc., Eugene, OR) and 10 eq of DIPEA in a microcentrifuge
tube, and the reaction was allowed to proceed for 2 to 3 h at room temperature
with occasional mixing. After several washes with DMF, t-amyl alcohol, glacial
acetic acid, and diethyl ether, the resin was dried under vacuum. The dye-
conjugated peptides were cleaved from the resin, and the side chain-protecting
groups were removed by incubating in reagent K (TFA-phenol-thioanisole-wa-
ter-ethane dithiol [82.5:5:5:5:2.5]) for 3 h at room temperature. The labeled
peptides were purified by reversed-phase high-pressure liquid chromatography
as described above. The concentration of peptides was determined by using the
Lowry method (16).
Fluorescence measurements: anisotropy and quenching. All fluorescence
studies were performed in a Hitachi F-3010 spectrofluorometer with a facility for
spectrum addition and subtraction. The excitation and emission band passes
were 5 nm unless stated otherwise. Fluorescence anisotropy measurements (8)
were done by using a Hitachi polarizer accessory. The steady-state fluorescence
anisotropy (A) was calculated according to the following equation:
A
I GI
I 2GI
(1)
where I is the intensity when the polarizers were in the same direction, I is the
intensity when the polarizers were crossed, and G is the grating factor that
corrects for wavelength-dependent distortion of the polarizing system. For each
anisotropy value, three measurements were taken and averaged. FITC-conju-
gated peptides (800 nM) were titrated separately with increasing concentrations
of Hsp16.3 in 50 mM sodium phosphate buffer (pH 7.5) containing 300 mM NaCl
at room temperature (25 
 1°C). The excitation and emission were 495 and 519
nm, respectively.
A single-step binding model was used for the analysis of the binding isotherm
of the peptides (10 and 22). The anisotropy (A) data were fitted to the analytical
formula (equation 2) by using the Marquardt nonlinear least squares algorithm.
The parameters of the fit were the anisotropies of free and bound peptides (Af
and Ab, respectively) and the dissociation constant KD.
A Af Ab Af ·
(Peptot Protot KD) (Peptot Protot KD)2 4 · Peptot · Protot2 · Peptot 
(2)
The total concentrations of peptide 10 or 22, Peptot, and protein Protot were
known in these experiments.
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For tyrosine fluorescence quenching studies (4, 15) excitation and emission
wavelengths were 280 and 311 nm, respectively. The respective band passes were
5 and 10 nm. The observed fluorescence values were corrected for volume
change and inner filter effect. The inner filter effect was corrected by using the
following formula:
Fcorr Fobs antilog Aex Aem2  (3)
where Aex is the absorbance at the excitation wavelength and Aem is the absor-
bance at the emission wavelength. The buffer used for this experiment was the
same as mentioned earlier. Binding of peptide 10 (Seq ID 10) was determined
from quenching of tyrosine fluorescence of Hsp16.3. Hsp16.3 (5 and 15 M) was
titrated with increasing concentrations of peptide 10. F/F0 was plotted against
peptide 10 concentration, where F0 is the initial fluorescence and F is the
fluorescence value after quenching at each point. The ratio of F/F0 is assumed to
be equal to the degree of binding.
All curve fittings and statistical deductions were done by using Kyplot software
(K. Yoshioka, 1997–1999, version 2.0 beta 4). The results have been presented as
the mean 
 the standard error (SE), calculated from three independent exper-
iments. The significance levels are indicated, wherever relevant, by the P value.
P values of 0.05 are considered significant.
In vitro assay for anti-Hsp16.3 activity. Aggregation of 5 M ADH at 50°C
was measured as the apparent optical density at 360 nm by using a Hitachi
spectrophotometer equipped with a thermostated cuvette holder in a total reac-
tion volume of 500 l. The optical density was monitored continuously until
steady-state levels were reached. The absorbance values at 100-s intervals were
retrieved and plotted against time. Intra-assay variations of absorbance values
with the same protein stock solutions were 1%. The chaperone activity of
Hsp16.3 was determined by mixing ADH with Hsp16.3 at a molar ratio of 5:4,
and aggregation rates were again determined by continuous spectrophotometric
monitoring as described above. The same experiment was then performed in the
presence of increasing concentrations of the Hsp16.3 binding peptides. The
percent residual chaperone activity was plotted against peptide concentration,
and from such a plot the inhibitory concentration at which 50% activity was lost
(IC50) was calculated by using a nonlinear regression data analysis in Kyplot (K.
Yoshioka, 1997–1999, version 2.0 beta 4).
Formation and analysis of Hsp16.3-substrate complex. Hsp16.3 was mixed
with MDH in a 40:1 molar ratio in 50 mM sodium phosphate buffer (pH 7.5),
containing 300 mM NaCl (20 l total volume) in a 1.5-ml microcentrifuge tube,
followed by incubation at 50°C for 30 min. Samples were then centrifuged at
room temperature for 15 min at 15,000  g. Both supernatants and pellet
fractions were analyzed by SDS-PAGE on a 15% gel. Band intensities were
determined by densitometric scanning using a GS-700 imaging densitometer
(Bio-Rad Laboratories) and analyzed by the supplied Molecular Analyst (version
1.5) software.
NMR spectroscopy. All NMR spectra were obtained with a Bruker DRX-500
NMR spectrometer equipped with a Z-field gradient probe. All measurements
were done in high-precision 5-mm NMR tubes in 20 mM sodium phosphate
buffer (pH 7.0) containing 250 mM NaCl in 90% H2O and 10% D2O. All NMR
experiments were done at 5°C unless stated otherwise. Total correlation spec-
troscopy (TOCSY) spectra were measured by using standard pulse sequences in
the Bruker pulse library using the WATERGATE water suppression method.
Standard Bruker software (Xwin-NMR, version 1.3) was used to acquire and
process the NMR data. The peptide 10 concentration was 2 mM. When present,
the Hsp16.3 concentration was 0.1 mM, thus making a 20-fold peptide excess
over the binding sites.
RESULTS
Biological enrichment of phage displaying Hsp16.3 binding
peptide sequences through biopanning. After the third round
of panning of the Ph.D.-7 library on Hsp16.3, it was found that
out of the eight randomly selected phage clones (Seq IDs 1 to
8), which were sequenced for the peptide-coding region, five
were identical (Table 1). Seq ID 9 represents a consensus
sequence, Lys-Met-His-Ala-Thr-Asn-His, emerging from this
panning experiment. In the case of the Ph.D.-12 library, the
results were more striking. Of the 10 clones sequenced after
the third panning, 9 clones (Seq IDs 11 to 20) were identical,
and the consensus peptide sequence (Seq ID 21) in this case
was Tyr-Pro-His-His-Phe-Lys-His-Arg-His-Ile-Pro-Ile. When
the two consensus sequences (Seq IDs 9 and 21) were com-
pared, it was found that the third and seventh His residues
existed in an aligned position. The binding of phage clones
TABLE 1. Hsp16.3 binding peptide sequences selected after third-round panning
Phage display
library used
Sequence
IDa Amino acid sequence
b
Ph.D.-7 1 Gly Val Glu Asn Val Ser Trp
2 Lys Met His Ala Thr Asn His
3 Lys Met His Ala Thr Asn His
4 Lys Met His Ala Thr Asn His
5 Leu Pro Ala Lys Asn Phe His
6 Phe Pro Pro Leu Lys Ser Pro
7 Lys Met His Ala Thr Asn His
8 Lys Met His Ala Thr Asn His
9 Lys Met His Ala Thr Asn His
10† Lys Met His Ala Thr Asn His Gly Gly Gly Ser
Ph.D.-12 11 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
12 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
13 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
14 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
15 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
16 Ala Tyr Lys Pro Ile Ala His Phe Ile Ser Pro Ala
17 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
18 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
19 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
20 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
21 Tyr Pro His His Phe Lys His Arg His Ile Pro Ile
22† Tyr Pro His His Phe Lys His Arg His Ile Pro Ile Gly Gly Gly Ser
a ID, identification number. , the most frequently occurring sequence in the group: the consensus sequence. †, the spacer sequence (Gly-Gly-Gly-Ser) was added
to the C-terminal end of the consensus sequence as suggested by the suppliers of the Ph.D. kits (New England Biolabs) to derive the effective binding sequences.
b The His residues that are in aligned positions are in boldface.
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displaying peptides (Seq IDs 9 and 21) to Hsp16.3 was con-
firmed further by performing a reverse phage ELISA (Fig. 1).
For deriving synthetic peptides, the Gly-Gly-Gly-Ser spacer
was added to the consensus sequences at the C-terminal ends
to obtain the effective binding sequences having IDs 10 and 22.
The various Hsp16.3 binding peptide sequences mentioned
in the present study, the method of deriving them, and assay of
their inhibitory activities are all covered by a patent application
(pending) made to the U.S. Patent and Trademark Office.
Binding affinity of the peptide ligands for Hsp16.3. Seq IDs
10 and 22, referred to as peptides 10 and 22 henceforth, were
synthesized chemically and labeled with FITC at the N terminal
ends.
The fluoresceinated peptides were used to measure binding
with Hsp16.3 by fluorescence anisotropy. Figure 2A and B show
the titrations of FITC-conjugated peptides 10 and 22 (800 nM),
respectively, with increasing concentrations of Hsp16.3. For each
peptide three independent titrations were done, and the mean
anisotropy 
 the SE was plotted against protein concentration.
Anisotropy increased as a function of Hsp16.3 concentration. The
data were fitted to the single-site binding equation (equation 2),
and the dissociation constant was determined. The KD values thus
obtained were found to be 54.2 
 13.7 M (P  0.001) and
45.7 
 18.0 M (P  0.023) for peptides 10 and 22, respectively.
Tyrosine fluorescence quenching of Hsp16.3 protein was
also used to study the binding of peptide 10. Since peptide 10
has no tyrosine residues, it can be used as a quencher, but a
similar exercise could not be done in the case of peptide 22
since tyrosine forms a part of the sequence. Figure 2C shows
the tyrosine fluorescence quenching profile of Hsp16.3 (15
M) upon binding peptide 10. The abscissa value of the inter-
section of the asymptotic line and that drawn through the
initial F/F0 values represents nPt  KD, where n is the number
of peptide binding sites per subunit of Hsp16.3 and Pt is the
total protein concentration in terms of monomer. In order to
determine n, the quenching experiments were done at two
concentrations of Hsp16.3: 15 M (Fig. 2C) and 5 M (data
not shown). The abscissa values were found to be 20.0 (Fig.
2C) and 10.2 M, respectively. Hence, we have KD  15n 
20.0 and KD  5n  10.2. By eliminating KD from these two
equations, the value of n was determined to be 0.98. It may be
concluded that there is one binding site for peptide 10 per
subunit of Hsp16.3.
Specific inhibition of Hsp16.3 chaperone activity by the pep-
tides. Alcohol dehydrogenase (ADH) (5 M) aggregates when
heated to 50°C (Fig. 3A, B, D, and E). This aggregation is
inhibited to the extent of ca. 85% when ADH is coincubated
with Hsp16.3 (Fig. 3A and D) at a molar ratio of ADH to
Hsp16.3 of 5:4. The addition of increasing amounts of peptide
10 resulted in progressive loss of the chaperone activity of
Hsp16.3. At the highest concentration of 100 M, i.e., at an
25-fold molar excess, a significant inhibition (70%) of
chaperone activity was observed (Fig. 3A). Similarly, in the
case of peptide 22, the extent of inhibition at 100 M was ca.
60% (Fig. 3D). The addition of peptide alone did not have any
effect on aggregation rates of ADH (Fig. 3A and D). Using the
same experimental setup, Hsp16.3 was replaced by alphaB-
crystallin, and the inhibitory effect, if any, of the peptides on
this protein was analyzed. As expected, when ADH (5 M) was
mixed with alphaB-crystallin (2.5 M), complete protection
against aggregation was observed, but this protection could not
be reversed by the addition of either peptide 10 or peptide 22
(Fig. 3B and E, respectively) at the concentration of 100 M,
which effectively gives an 40-fold molar excess of peptide
over the target protein alphaB-crystallin. To obtain a more
quantitative interpretation, the percent residual chaperone ac-
tivity (mean 
 the SE of three independent experiments) was
plotted against peptide concentration. This yielded a dose-
response curve (Fig. 3C and F) from which IC50 values of
53.0 
 8.47 M (P 0.0079) for peptide 10 and of 57.1 
 4.37
M (P  0.0058) for peptide 22 were obtained. The dose-
response curves for both peptides also show graphically that in
the context of alphaB-crystallin there was almost no effect.
Peptides affect the stability of Hsp16.3-substrate complexes.
It has been demonstrated earlier that alpha-HSPs form soluble
complexes with aggregation-prone proteins when heated to-
gether at 50°C (14). In order to investigate the possible mech-
anism of action of the peptide inhibitors, their effect on
Hsp16.3-substrate complex formation was examined by using
the model substrate malate dehydrogenase (MDH). MDH was
taken at a concentration of 2 M and heated at 50°C. As
expected, it formed aggregates and precipitated out. When the
pellet and supernatant were analyzed by SDS-PAGE, the
entire protein was found to be present in the pellet fraction
(Fig. 4A, lane 2). Hsp16.3 (80 M) was then added to MDH at
a 40-fold molar excess prior to heating to prevent aggregation.
The incorporation of this amount gave maximal protection,
and most of the MDH was retained in the supernatant (Fig.
4A, lane 3). To investigate the effect of peptide 10 on complex
formation, increasing doses of the peptide were added to in-
FIG. 1. Reverse phage ELISA to confirm the binding of phage
clones displaying peptide sequences, Seq ID 9 and 21, to Hsp16.3. The
phage clones were amplified, concentrated by PEG precipitation, and
reacted with either Hsp16.3 or nonspecific target BSA coated on the
wells of a microtiter plate. Unbound phage was removed by washing
with TBST (0.5% Tween 20), and bound phage was detected with
horseradish peroxidase-conjugated anti-M13 monoclonal antibody
(1:5,000) and ABTS substrate. Color development was monitored
spectrophotometrically at 405 nm. Each experiment was done in trip-
licate. The bar graph shows binding activity of phage clones displaying
Seq ID 9 () and Seq ID 21 (■) to Hsp16.3 and BSA (background
binding). The error bars represent the SE.
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activate Hsp16.3. Figure 4B shows a progressive shift in the
MDH band from the supernatant to the pellet fraction (lanes
marked by black dots) upon addition of increasing amounts of
peptide 10. Hsp16.3, however, remained soluble up to a 3.2
mM concentration of peptide 10 (40-fold molar excess), al-
though at a higher concentration (4.8 mM, i.e., a 60-fold molar
excess) it was also precipitated (Fig. 4D). Addition of peptide
22 led to similar consequences (Fig. 4C), but in this case almost
complete precipitation of the complex occurred at a 1.2 mM
peptide concentration (15-fold molar excess) compared to 4.8
mM (60-fold molar excess) in the case of peptide 10. Another
notable difference was that, unlike the previous case, precipi-
tation of Hsp16.3 and MDH occurred in parallel when peptide
22 was used as an inhibitor (Fig. 4E). Since in both cases a
detectable loss in the solubility of Hsp16.3 was observed, the
effect of these peptides on the solubility of Hsp16.3 itself was
examined at the peptide concentrations at which the com-
plexes were precipitated. The results indicate that in the case
of peptide 10 (Fig. 4F), ca. 70% of the chaperone protein
present became insoluble at a 60-fold molar excess (4.8 mM),
whereas in the case of peptide 22 (Fig. 4G), almost 90% of it
lost solubility at a 15-fold molar excess (1.2 mM).
Although the precipitation was observed at relatively high
concentrations of peptides, the phenomenon is specific since it
does not occur in case of BSA and DnaK (data not shown), nor
does it affect the related homologue alphaB-crystallin (Fig.
4H). Thus, when a 15-fold molar excess (1.2 mM) of peptide 22
was added to Hsp16.3 (80 M), a significant loss of solubility
was observed as expected (Fig. 4H, lane 4), but when it was
added to alphaB-crystallin, no effect was observed (Fig. 4H,
lane 8). The effect of the peptides on the complex between
MDH and alphaB-crystallin was also investigated (Fig. 4I).
The results presented for peptide 22 show that at the concen-
tration of the peptide at which Hsp16.3-MDH complex pre-
cipitates out (Fig. 4I, lane 4), no effect on alphaB-crystallin–
MDH complex (Fig. 4I, lane 8) was observed. The assays were
repeated several times, and the precipitation pattern was found
to be reproducible. These observations further establish that
the peptide inhibitors have target specificity.
Precipitation is not an essential feature for inhibition. In
order to investigate whether the loss of chaperone activity of
Hsp16.3 observed in the spectrophotometric aggregation as-
says was due to precipitation of the protein, an assay (Fig. 5A)
was first performed essentially as described in the previous
sections and then, after reaching steady-state aggregation, the
samples were centrifuged, and pellet fractions were analyzed
by SDS–15% PAGE (Fig. 5C). The presence of Hsp16.3 (4
M) prevents aggregation to an extent of 60% (Fig. 5A and B).
FIG. 2. Determination of the dissociation constant and stoichiometry of peptide binding to Hsp16.3. Anisotropy increase of FITC-labeled
peptide 10 (A) and peptide 22 (B) as a function of Hsp16.3 concentration in 50 mM sodium phosphate buffer (pH 7.5) containing 300 mM NaCl
at room temperature. Anisotropy values are means 
 the SE (indicated by error bars) of three independent experiments. The excitation and
emission wavelengths were at 495 and 519 nm, respectively. In case of peptide 10, stoichiometry was determined (C) from the dose-dependent
quenching of the intrinsic tyrosine fluorescence of Hsp16.3 in the same buffer conditions. The lines were drawn to determine binding stoichiometry.
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Addition of peptide 10 or peptide 22 at a 50-fold molar excess
(200 M) restored aggregation to almost the initial level
(ADH alone). Hsp16.3 itself does not show any aggregation.
SDS-PAGE analysis revealed that in presence of Hsp16.3
there was a 55% drop in the intensity of the ADH band (Fig.
5C and D, lane 3) commensurate with the drop observed in the
spectrophotometric assay. In the presence of the peptides, the
intensity returned to almost 100%, indicating inhibition of
Hsp16.3 activity (Fig. 5C and D, lanes 4 and 5 compared to
lane 2). The fluctuations in intensities occurred only in the case
of the ADH bands but not for Hsp16.3, the intensity of which
remained at the background levels (Fig. 5D). This indicates
that under the conditions of the spectrophotometric assay the
inactivation by the peptides does not involve aggregation of
FIG. 3. Dose-dependent inhibition of chaperone activity of Hsp16.3 by peptides 10 and 22. Aggregation assays were performed by heating
5 M ADH at 50°C directly in a spectrophotometer using a thermostated cuvette holder in a total reaction volume of 500 l in 100 mM sodium
phosphate buffer (pH 7.0) containing 100 mM NaCl. The absorbance was monitored at 360 nm for 1,200 s, and readings were taken at every 100-s
interval. ADH aggregates upon heating (A, B, D, and E; Œ). Incorporation of Hsp16.3 at a molar ratio of 5:4 (A and D) or alphaB-crystallin at
a molar ratio of 1:1 (B and E) results in a decline in aggregation activity (F). Then increasing concentrations of Hsp16.3 binding peptide 10 (A
and B) and peptide 22 (D and E) were added as indicated at the following concentrations: 25 M (), 50 M (■), and 100 M (‚). Stars represent
the ADH aggregation in the presence of peptide 10 (A and B) and peptide 22 (D and E). The IC50 for peptide 10 (C) and peptide 22 (F) was
calculated from the plot of the percent residual chaperone activity against the peptide concentration. Each datum point in panels C and F is an
average of three independently derived results. Error bars indicate the SE.
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Hsp16.3. The result suggests that the binding of the peptides
alters the conformation of Hsp16.3 so that it becomes less
soluble, but the loss of solubility is actually manifested when
the concentrations of peptides are high, i.e., in the millimolar
range. Precipitation, therefore, is not the phenomenon itself
but a reflection of a possible conformational change in Hsp16.3
as a result of peptide binding.
Evidence for involvement of His residues in the interaction
of peptide with Hsp16.3. In order to further investigate the
interaction between peptides and Hsp16.3, NMR experiments
were performed. Figure 6A represents the overlaid TOCSY
spectra of the NH-H region of peptide 10 (2 mM) in the
absence of Hsp16.3 (red) and in the presence of Hsp16.3
(blue) at a substoichiometric concentration (0.1 mM). Under
these ligand excess conditions, only the peptide peaks are vis-
ible. The fast exchange between the receptor bound and free
forms allows averaging of the two chemical shifts under two
different conditions. Thus, the chemical shift change, com-
pared to the free peptide, represents chemical shifts that are
different in the receptor bound state and possible points of
FIG. 4. Effect of peptides on the stability of the Hsp16.3-MDH complex. (A) MDH (2 M) either alone or after being mixed with Hsp16.3
(80 M) was heated to 50°C for 30 min, followed by centrifugation at 15,000  g. The supernatants and pellets were analyzed by SDS-PAGE on
a 15% gel. Lanes marked with black dots represent pellet fractions in all cases. The MDH-Hsp16.3 complex was then formed in the presence of
inhibitory peptide 10 or peptide 22 (B and C), respectively. The molar excesses of the peptides used relative to Hsp16.3 are indicated below the
lanes. The bands were scanned densitometrically, and the fraction of the protein (either Hsp16.3 or MDH) that appeared in the supernatant was
plotted as the percent solubility against the molar excess of peptide 10 or peptide 22 (D and E), respectively. (F and G) The effect of peptides 10
and 22 on the solubility of Hsp16.3 was tested using the indicated molar excess. (H) The comparative effect of peptide 22 (lanes marked with black
dots) on alphaB-crystallin was determined side by side with the Hsp16.3 control. (I) Similarly, the effect of peptide 22 on the formation of a soluble
complex between alphaB-crystallin and MDH was tested alongside an Hsp16.3-MDH control. In the last two experiments, a peptide molar excess
of 15 over either Hsp16.3 or alphaB-crystallin was used.
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interaction between the peptide and the receptor. Figure 6B
graphically represents the chemical shift differences of amide
protons of peptide 10 residues in buffer solutions in the pres-
ence or absence of Hsp16.3. It is clear from the bar diagram
that only a few residues shift and that chemical shift of most of
the residues remains unchanged. The residue types were as-
signed from spin connectivity and chemical shift information
(data not shown). The peaks for Met were not observed in the
TOCSY spectra, probably because of broadening of peaks due
to conformational exchange. The peak for Met could, however,
be observed when the spectra were derived in water at 27°C
(data not shown), confirming that the peptide contained Met.
The comparison of TOCSY spectra of peptide 10 obtained in
the presence or absence of Hsp16.3 revealed significant chem-
ical shift changes for both His residues of peptide 10 in the
presence of Hsp16.3. In the case of Ala, a minor effect was
observed, but for the others the effect was negligible. From this
result it appears that the His-X-Y-Y-His region of peptide 10
may be necessary for interaction with Hsp16.3, where X stands
for Ala or an analogous amino acid and Y represents any other
amino acid. A similar analysis with peptide 22 was not possible
since the peptide 22-Hsp16.3 complex precipitates out at high
concentration, as has been demonstrated earlier.
DISCUSSION
Low-molecular-weight HSPs (sHSPs) play a major role in
the maintenance of protein stability under stress conditions
(6). The most well-known examples of sHSPs are the lens
proteins alpha-crystallin A and B, which are implicated in the
maintenance of lens transparency. Alpha-crystallin-like pro-
teins (alpha-HSPs) are, however, ubiquitous in nature, being
present in animals, plants, and also bacteria. Functionally,
these proteins have been classified as chaperones since they
can prevent thermal denaturation of proteins. This feature is
common to all sHSPs, and hence prevention of aggregation of
FIG. 5. Peptide-mediated inactivation of Hsp16.3 under conditions used for spectrophotometric assay of chaperone activity. (A) The chaperone
activity was measured spectrophotometrically as described in Fig. 3. Aggregation of ADH (5 M) without chaperone is represented by the curve
marked by white circles, protection by Hsp16.3 (4 M) by black circles, and inhibition of Hsp16.3 by peptides 10 and 22 (200 M) by white and
black squares, respectively. Aggregation of Hsp16.3 alone is indicated by white triangles. (B) The steady-state aggregations (1,200 s) observed in
panel A are graphically represented. (C) The aggregated samples were centrifuged, and the pellet fractions were analyzed by SDS-PAGE on a 15%
gel; lanes corresponding to the aggregation curves are indicated by identical symbols. The combinations of proteins and peptides used are indicated
on the top. The bar diagram (D) shows the band intensities of the ADH () and Hsp16.3 (■) components in each lane.
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proteins is considered a standard assay for their activity. Ag-
gregation prevention, however, is not the only function of these
proteins, and there is evidence to show that they are implicated
in cytomorphological reorganization and signal transduction
events (10).
This is possibly the first report where an attempt to develop
an inhibitor against an alpha-HSP has been made. The impor-
tance of alpha-HSPs in human eye lens physiology demands
that all efforts be made to prevent rather than cause inhibition
of activity. In the case of bacteria, however, there is a paradigm
shift. Since sHSPs play an important role in the survival of
bacteria under stress conditions, their inactivation may be an
important issue, particularly in the context of intracellular
pathogens such as M. tuberculosis, which use sHSPs to survive
various challenges (30). The present investigation shows that it
should be possible to derive a specific inhibitor against the
mycobacterial virulence factor Hsp16.3 without inhibiting
functionally similar human counterparts such as alphaB-crys-
tallin (25).
The binding affinity that is represented by the KD is in the
range of 50 M for both entities. The determination of KD was
done by performing anisotropic titrations using fluoresceinated
peptides. We have used a single site binding equation to obtain
an estimate of KD for the peptides. In the case of peptide 10,
the assumption that binding stoichiometry is one per subunit of
Hsp16.3 seems to work well, as indicated by the low P value
(0.001) associated with the determined KD. The quenching
experiments also support such a model for peptide 10 since the
stoichiometry was determined to be one binding site per sub-
unit of Hsp16.3. In the case of peptide 22, the P value (0.023)
of KD determination is relatively higher, which indicates a
lower level of significance. It is possible that in the case of
peptide 22 the binding may be explained by a more complex
model. However, the true binding affinities could be higher
than those obtained from anisotropic titrations, as is evident
from the quenching experiment performed using peptide 10.
Although a precise KD determination from this experiment was
not feasible (the protein concentration should be much lower
than the KD for its accurate determination), an approximate
estimate revealed a value of 5 M, indicating that the un-
modified peptide possibly has a higher affinity. The higher KD
obtained from anisotropic titrations may be due to steric hin-
drance contributed by the conjugated fluorophore (i.e., FITC).
Members of the alpha-HSP superfamily include three re-
gions, a characteristic alpha-crystallin domain, which is flanked
by a short variable C-terminal extension, and a poorly con-
served N-terminal region (18). The alpha-HSPs are generally
highly soluble proteins, which is expected since they are re-
quired to maintain the solubility of other proteins. However,
during chaperone action, the hydrophobic surfaces (29) are
exposed, allowing the possibility of loss of solubility. However,
this does not happen because of the flexible C-terminal exten-
sions (6), which serve as solubilizers. The C-terminal exten-
sions are rich in polar amino acid residues, and any replace-
ment that gives a hydrophobic character results in severe loss
of not only chaperone function but also solubility (23). Solu-
bility and chaperone function of alpha-HSPs are thus inter-
linked, and any agent that affects one is likely to affect the
other. It is therefore not unexpected that the peptides, which
cause inhibition of chaperone activity, also cause precipitation.
The loss of chaperone activity occurs at relatively low con-
centrations, whereas precipitation requires a higher concentra-
tion of both peptide and target. The effect of the peptides on
the protein appears to be manifested at two levels. At lower
concentrations these peptides bind to high-affinity binding
sites, with KDs in the micromolar range, resulting in functional
inhibition. This inhibition may be due to the peptides compet-
ing for the active site in a manner resembling histatins—anti-
microbial peptides known to act as inhibitors by serving as
pseudosubstrates or by tight binding to the active site, elimi-
nating the accessibility to the natural substrates (11). Alterna-
tively, the mode of action may resemble that of pyrrohocoricin,
another antimicrobial peptide that binds not to the active site
but to the regulatory region of DnaK, thereby inhibiting its
function (20). At higher concentrations it appears that second-
ary sites are engaged, resulting in the loss of solubility. Since
both peptides are highly cationic in nature, it is possible that,
subsequent to binding, the peptides disrupt charge-charge
interactions that are generally considered necessary for main-
FIG. 6. Changes in chemical shift of peptide 10 residues due to
interaction with Hsp16.3. (A) Overlay 2D TOCSY spectra in the fin-
gerprint (selected) region of 2 mM peptide 10 in 20 mM sodium
phosphate buffer (pH 7.0) containing 250 mM NaCl in 90% H2O and
10% D2O at 5°C in the absence (red) or in the presence (blue) of 0.1
mM Hsp16.3 protein. Amino acids are designated by using the one-
letter code. (B) Graphical representation of chemical shift differences
(  Hz) of amide protons of peptide 10 residues in buffer solution in
the presence or absence of Hsp16.3, as mentioned in the legend to
panel A.
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taining both the structural integrity and solubility of alpha-
HSPs (5). Such a hypothesis accounts for the fact that peptide
22, which is more cationic, could precipitate out Hsp16.3, as
well as the Hsp16.3-MDH complex, more efficiently than could
peptide 10. However, the destabilization effect seems to have
some degree of specificity, since the alphaB-crystallin–MDH
complex was not affected by the presence of high concentra-
tions of peptide 22.
The chemical shift changes involving His residues of peptide
10 suggest their involvement in the peptide-protein interac-
tions. It may be noted here that peptide 22, like peptide 10,
also contains several histidines, two of these being in aligned
positions. When the Protein Information Resource database
(3) was scanned for M. tuberculosis proteins carrying a His-X-
X-X-His signature (where X stands for any amino acid), a large
number of hits were found. Several of these contained signa-
tures that closely resembled either the peptide 10 or peptide 22
sequences. It is speculated that some of these proteins may be
the natural substrates of Hsp16.3. Thus, by this approach it
may be possible to obtain clues regarding substrate specificities
of not only Hsp16.3 but other members of the alpha-HSP
family as well. In this context it may be mentioned that a
similar approach based on screening phage display libraries
had been used earlier to determine substrate preferences of
DnaK (12).
The inhibitory effects described have been demonstrated by
using in vitro assays. Since no other assay was available, chap-
erone function was targeted. As has been stressed earlier,
Hsp16.3 may have other functions apart from chaperone ac-
tivity. In that case, the in vitro assays may not reflect or only
partly reflect the in vivo situation. A direct demonstration of
antimycobacterial activity would thus be necessary. However, it
must be emphasized that Hsp16.3 does not have a role to play
in the viability of actively growing bacteria. It is only in dor-
mancy that it plays a vital role in survival. Hence, to demon-
strate the antimycobacterial activity, these peptides need to be
tested with anaerobic models (28). The penetration of the
lipid-rich cell envelopes of mycobacteria has always been a
major impediment in developing drugs and therefore issues
such as penetration of membrane barriers and stability in vivo
need to be resolved. Antimicrobial peptides are common in
nature (1, 11, 19). Most of these peptides are cationic and
amphipathic. Some of these, such as defensins or maganins,
function by acting on cell membranes, whereas others, such as
histatins or NAP-2 are known to act as pseudo-substrate in-
hibitors as mentioned earlier. Pyrrhocoricin, the insect-derived
antimicrobial peptide, is an interesting case (20). It binds
DnaK of gram-negative bacteria without affecting the human
counterpart. This is a remarkable example of a naturally oc-
curring antibacterial peptide that targets a well-conserved pro-
tein in a species-selective manner. Peptides 10 and 22 thus
appear to function in a manner similar to pyrrhocoricin since
they, too, inhibit a relatively conserved protein. The absence of
reactivity of these peptides toward the lens protein is an indi-
cation that although there are elements of conservation, the
two proteins are sufficiently diverse to allow inactivation of one
(Hsp16.3) without affecting the other (alphaB-crystallin).
However, for a peptide to have antimicrobial property it
should have some elementary properties (13); one of these is
cationic character. It has been suggested that the cationic char-
acter helps in membrane disruption. Both of the peptide in-
hibitors reported here satisfy this criterion. The other impor-
tant feature is amphipathicity (11), which is necessary for
membrane permeability. Apparently, neither of these two pep-
tides has the necessary amphipathicity, as is evident from a
search conducted at one website (http://aps.unmc.edu/AP
/main.php) (27). An alternative approach would be to look for
homologous peptides, which are known to have antimicrobial
activity, and to test their activity against Hsp16.3. Two such
peptides that could be considered potential candidates are
histatin 5 (AP00503) and histatin 8 (AP00523). They are both
derived from histatins, which are histidine-rich peptides pro-
duced by the salivary glands of humans. It has been suggested
that histatins may be used to combat Pseudomonas aeruginosa
infections in the airways of cystic fibrosis patients (21). It would
be interesting to study the effect of histatins on Hsp16.3 on one
hand and on mycobacterial viability on the other.
A point that has been emphasized earlier is that inhibition
has been demonstrated only in the context of chaperone activ-
ity. However, the protein could have other functions. Whether
these other functions would also be inhibited remains to be
seen, but it can be argued that the peptides were selected solely
on the basis of binding activity; therefore, there is no reason to
presume that inhibition would be targeted against one func-
tion, leaving aside the others. Even if that happens, it should be
possible to expand the repertoire of binding sequences through
further screening of phage display libraries. The peptide se-
quences described here may therefore be considered essen-
tially as “leads.” Their efficacies may be further enhanced
through biochemical/biophysical studies and modeling. Even if
the peptide inhibitors do not actually evolve into effective
drugs, they could be used as tools to understand better the
function of Hsp16.3 in particular and alpha-HSPs in general.
ACKNOWLEDGMENTS
We thank Juraj Ivanyii of MRC London for the Hsp16.3-expressing
clone EC-16. We thank K. P. Das for giving us substantial amounts of
recombinant alphaB-crystallin derived from a recombinant plasmid
originally developed by W. Boelens and W. W. de Jong. We thank W.
Boelens for consent to use the recombinant alphaB-crystallin protein
for the comparative studies.
We thank CSIR, Government of India, for financial support under
the New Millennium India Technology Leadership Initiative.
REFERENCES
1. Andreu, D., and L. Rivas. 1998. Animal antimicrobial peptides: an overview.
Biopolymers 47:415–433.
2. Appeldoorn, C. C., T. J. Molenaar, A. Bonnefoy, S. H. van Leeuwen, P. A.
Vandervoort, M. F. Hoylaerts, T. J. van Berkel, and E. A. Biessen. 2003.
Rational optimization of a short human P-selectin-binding peptide leads to
nanomolar affinity antagonists. J. Biol. Chem. 278:10201–10207.
3. Barker, W. C., J. S. Garavelli, H. Huang, P. B. McGarvey, B. C. Orcutt, G. Y.
Srinivasarao, C. Xiao, L. L. Yeh, R. S. Ledley, J. F. Janda, F. Pfeiffer, H.
Mewes, A. Tsugita, and C. Wu. 2000. The protein information resource
(PIR). Nucleic Acids Res. 28:41–44.
3a.Barry, C., III. November 2002. Method of attenuating pathogenic mycobac-
teria and strains of mycobacteria so attenuated. U.S. patent 6,403,100.
4. Bhattacharyya, T., A. Bhattacharyya, and S. Roy. 1991. A fluorescence
spectroscopic study of glutaminyl-tRNA synthetase from Escherichia coli and
its implications for the enzyme mechanism. Eur. J. Biochem. 200:739–745.
5. Boelens, W. C., Y. Croes, M. de Ruwe, L. de Reu, and W. W. de Jong. 1998.
Negative charges in the C-terminal domain stabilize the alphaB-crystallin
complex. J. Biol. Chem. 273:28085–28090.
6. Carver, J. A. 1999. Probing the structure and interactions of crystallin pro-
teins by NMR spectroscopy. Prog. Retin. Eye Res. 18:431–462.
7. Chang, Z., T. P. Primm, J. Jakana, I. H. Lee, I. Serysheva, W. Chiu, H. F.
Gilbert, and F. A. Quiocho. 1996. Mycobacterium tuberculosis 16-kDa antigen
VOL. 71, 2005 PEPTIDE INHIBITORS OF A MYCOBACTERIAL VIRULENCE FACTOR 7343
(Hsp16.3) functions as an oligomeric structure in vitro to suppress thermal
aggregation. J. Biol. Chem. 271:7218–7223.
8. Chattopadhyay, R., and S. Roy. 2002. DnaK-sigma 32 interaction is temper-
ature dependent: implication for the mechanism of heat shock response.
J. Biol. Chem. 277:33641–33647.
9. Coates, A., Y. Hu, R. Bax, and C. Page. 2002. The future challenges facing
the development of new antimicrobial drugs. Nat. Rev. Drug Discov. 1:
895–910.
10. de Jong, W. W., J. A. Leunissen, and C. E. Voorter. 1993. Evolution of the
alpha-crystallin/small heat-shock protein family. Mol. Biol. Evol. 10:103–126.
11. Epand, R. M., and H. J. Vogel. 1999. Diversity of antimicrobial peptides and
their mechanisms of action. Biochim. Biophys. Acta 1462:11–28.
12. Gragerov, A., L. Zeng, X. Zhao, W. Burkholder, and M. E. Gottesman. 1994.
Specificity of DnaK-peptide binding. J. Mol. Biol. 235:848–854.
13. Groisman, E. A. 1996. Bacterial responses to host-defense peptides. Trends
Microbiol. 4:127–129.
14. Lee, G. J., A. M. Roseman, H. R. Saibil, and E. Vierling. 1997. A small heat
shock protein stably binds heat-denatured model substrates and can main-
tain a substrate in a folding-competent state. EMBO J. 16:659–671.
15. Lin, S. X., Q. Wang, and Y. L. Wang. 1988. Interactions between Escherichia
coli arginyl-tRNA synthetase and its substrates. Biochemistry 27:6348–6353.
16. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein
measurement with the Folin phenol reagent. J. Biol. Chem. 193:265–275.
17. Michele, T. M., C. Ko, and W. R. Bishai. 1999. Exposure to antibiotics
induces expression of the Mycobacterium tuberculosis sigF gene: implications
for chemotherapy against mycobacterial persistors. Antimicrob. Agents Che-
mother. 43:218–225.
18. Narberhaus, F. 2002. Alpha-crystallin-type heat shock proteins: socializing
minichaperones in the context of a multichaperone network. Microbiol. Mol.
Biol. Rev. 66:64–93.
19. Otvos, L., Jr. 2000. Antibacterial peptides isolated from insects. J. Pept. Sci.
6:497–511.
20. Otvos, L., Jr., I. O, M. E. Rogers, P. J. Consolvo, B. A. Condie, S. Lovas, P.
Bulet, and M. Blaszczyk-Thurin. 2000. Interaction between heat shock pro-
teins and antimicrobial peptides. Biochemistry 39:14150–14159.
21. Sajjan, U. S., L. T. Tran, N. Sole, C. Rovaldi, A. Akiyama, P. M. Friden, J. F.
Forstner, and D. M. Rothstein. 2001. P-113D, an antimicrobial peptide active
against Pseudomonas aeruginosa, retains activity in the presence of sputum
from cystic fibrosis patients. Antimicrob. Agents Chemother. 45:3437–3444.
22. Scott, J. K., and G. P. Smith. 1990. Searching for peptide ligands with an
epitope library. Science 249:386–390.
23. Smulders, R. H. P. H., J. A. Carver, R. A. Lindner, M. A. van Boekel, H.
Bloemendal, and W. W. de Jong. 1996. Immobilization of the C-terminal
extension of bovine alphaA-crystallin reduces chaperone-like activity. J. Biol.
Chem. 271:29060–29066.
24. Stewart, G. R., B. D. Robertson, and D. B. Young. 2003. Tuberculosis: a
problem with persistence. Nat. Rev. Microbiol. 1:97–105.
25. Valdez, M. M., J. I. Clark, G. J. Wu, and P. J. Muchowski. 2002. Functional
similarities between the small heat shock proteins Mycobacterium tuberculo-
sis HSP 16.3 and human alphaB-crystallin. Eur. J. Biochem. 269:1806–1813.
26. Verbon, A., R. A. Hartskeerl, A. Schuitema, A. H. Kolk, D. B. Young, and R.
Lathigra. 1992. The 14,000-molecular-weight antigen of Mycobacterium tu-
berculosis is related to the alpha-crystallin family of low-molecular-weight
heat shock proteins. J. Bacteriol. 174:1352–1359.
27. Wang, Z., and G. Wang. 2004. APD: the antimicrobial peptide database.
Nucleic Acids Res. 32(database issue):D590–D592.
28. Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study
of shiftdown of Mycobacterium tuberculosis through two stages of nonrepli-
cating persistence. Infect. Immun. 64:2062–2069.
29. Yang, H., S. Huang, H. Dai, Y. Gong, C. Zheng, and Z. Chang. 1999. The
Mycobacterium tuberculosis small heat shock protein Hsp16.3 exposes hydro-
phobic surfaces at mild conditions: conformational flexibility and molecular
chaperone activity. Protein Sci. 8:174–179.
30. Yuan, Y., D. D. Crane, and C. E. Barry III. 1996. Stationary phase-associated
protein expression in Mycobacterium tuberculosis: function of the mycobac-
terial alpha-crystallin homolog. J. Bacteriol. 178:4484–4492.
31. Yuan, Y., D. D. Crane, R. M. Simpson, Y. Q. Zhu, M. J. Hickey, D. R.
Sherman, and C. E. Barry III. 1998. The 16-kDa alpha-crystallin (Acr)
protein of Mycobacterium tuberculosis is required for growth in macrophages.
Proc. Natl. Acad. Sci. USA 95:9578–9583.
7344 SAHA ET AL. APPL. ENVIRON. MICROBIOL.
